LIM Kinase (LIMK)

LIMKs

LIM kinases (LIMKs) are important cell cytoskeleton regulators that play a prominent role in cancer manifestation and neuronal diseases. The LIMK family consists of two homologues, LIMK1 and LIMK2, which differ from one another in expression profile, intercellular localization, and function. The main substrate of LIMK is cofilin, a member of the actin-depolymerizing factor (ADF) protein family. When phosphorylated by LIMK, cofilin is inactive. LIMKs play a contributory role in several neurodevelopmental disorders and in cancer growth and metastasis.

LIM domain kinases (LIMK1 and 2) are substrate for Cdc42/Rac-PAK, and modulate actin dynamics by phosphorylating cofilin at serine-3. This modification inactivates cofilin's actin severing and depolymerizing activity. LIMKs also translocate into the nucleus and regulate cell cycle progression. LIMKs are potential therapeutic targets for NF2 and other merlin-deficient tumors.

LIM Kinase (LIMK) Inhibitors

Aurora/LIM kinase-IN-1

Cat. No.: HY-144438

Aurora/LIM kinase-IN-1 (Compound F114) is a potent and dual inhibitor of **aurora** and **lim** kinase. Aurora kinases and lim kinases are involved in neoplastic cell division and cell motility, respectively. Aurora/LIM kinase-IN-1 inhibits GBM proliferation and invasion.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BMS-3

Cat. No.: HY-18304

BMS-3 is a potent **LIMK** inhibitor with IC_{50}s of 5 nM and 6 nM for **LIMK1** and **LIMK2**, respectively.



Purity: 99.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BMS-5

(LIMKi 3)

Cat. No.: HY-18305

BMS-5 (LIMKi 3) is a potent **LIMK** inhibitor with IC_{50}s of 7 nM and 8 nM for **LIMK1** and **LIMK2**, respectively.



Purity: 99.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CRT0105950

Cat. No.: HY-120025

CRT0105950 is a potent **LIMK** inhibitor, with IC_{50}s of 0.3 nM and 1 nM for **LIMK1** and **LIMK2** respectively. CRT0105950 can be used for the research of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DD-03-156

((S,R,S)-AHPC-Me-PEG2-dabrafenib)

Cat. No.: HY-137346

DD-03-156 is a potent and selective degrader of **CDK17** and **LIMK2**. The selectivity and potency of DD-03-156 is exquisite and makes an advanced starting point for the development of a chemical probe for the degradation of CDK17.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

R-10015

Cat. No.: HY-120097

R-10015, a broad-spectrum antiviral compound for HIV infection, acts as a potent and selective inhibitor of **LIM domain kinase (LIMK)** and binds to the ATP-binding pocket, with an IC_{50} of 38 nM for human LIMK1.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SM1-71

Cat. No.: HY-136848

SM1-71 (compound 5) is a potent **TAK1** inhibitor, with a K_i of 160 nM, it also can covalently inhibit **MKNK2**, **MAP2K1/2/3/4/6/7**, **GAK**, **AAK1**, **BMP2K**, **MAP3K7**, **MAPKAPK5**, **GSK3A/B**, **MAPK1/3**, **SRC**, **YES1**, **FGFR1**, **ZAK (MLTK)**, **MAP3K1**, **LIMK1** and **RSK2**.



Purity: 96.00%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SR7826

Cat. No.: HY-19353

SR7826 is a class of bis-aryl urea derived potent, selective and orally active **LIM kinase (LIMK)** inhibitor with an IC_{50} of 43 nM for **LIMK1**. SR7826 is >100-fold more selective for **LIMK1** than ROCK and JNK kinases.



Purity: 98.74%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

T56-LIMKi

(T5601640)

Cat. No.: HY-19352

T56-LIMKi is a selective inhibitor of **LIMK2**; inhibits the growth of Panc-1 cells with an IC_{50} of 35.2 μM.



Purity: 98.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TH-257

Cat. No.: HY-122630

TH-257 is a potent inhibitor of **LIMK1** and **LIMK2** with IC_{50} values of 84 nM and 39 nM for **LIMK1** and **LIMK2**, respectively, and it can be used as a chemical probe for **LIMK1** and **LIMK2**.



Purity: 98.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg